Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Kira SheinermanManaging Director
Prior to joining Burrill & Company, Sheinerman was a Managing Director, Healthcare Investment Banking at Rodman & Renshaw. She joined Rodman in April of 2005 and worked on financial and strategic transactions for growth biotech companies with the focus on oncology, CNS, infectious diseases, and molecular diagnostics. Prior to her position at Rodman, she worked at The Arcus Group, specializing in analysis of market opportunities for early to late stage biotech products and in investment and acquisition opportunities in the fields of oncology and critical care. In 2008-2009 Sheinerman chaired the Board Executive Committee of Xenomics (now Trovagene, an MDx company listed on Nasdaq). She is a co-founder of DiamiR, LLC, a private company focused on development of minimally invasive screening tests based on analysis of cell-free organ-enriched miRNA. She is a board member of Boyce Thompson Institute, an affiliate of Cornell University, where she is a member of the investment and external relations committees. Sheinerman received a Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine for her work on molecular mechanisms of Alzheimer's disease. She also holds an MBA from the Honors program at Baruch College/CUNY. She and her husband live in New York City and have two daughters.